LONDON (Thomson Financial) - Curidium Medica PLC said it has filed worldwide trademark applications for PsychINDxTM as the name for its diagnostic test to classify patients with schizophrenia/bipolar disorder into four subgroups.
LONDON (Thomson Financial) - Curidium Medica PLC said it has filed worldwide trademark applications for PsychINDxTM as the name for its diagnostic test to classify patients with schizophrenia/bipolar disorder into four subgroups.
